News and Announcements
Dimerix Reports Successful Phase 2a Trial of DMX-200, with 36% reduction in proteinuria in patients with Diabetic Nephropathy
- Published December 14, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Phase 2a clinical trial for lead program DMX-200 was successfully completed.
- Data from this study met primary safety endpoint, with encouraging efficacy signals.
- Addition of Non-Executive Director Mr Hugh Alsop and Head of Drug Development Dr Robert Shepherd to the team.
- Share consolidation completed.
The successful completion of the Phase 2a clinical trial for our lead program, DMX-200, in Chronic Kidney Disease was the unequivocal highlight of the year. Not only did the data from this study meet the important primary endpoint of safety, the exciting and unexpected observation was that a statistically significant efficacy response was seen in the subgroup of patients with diabetic nephropathy. These clinical outcomes significantly enhance the underlying value proposition for DMX-200.
The year has also seen us bolster our team, complete a share consolidation and start marketing our trial data to pharmaceutical partners and investors on the world stage.
About Dimerix Limited (ASX: DXB)
Dimerix Limited (ASX: DXB) is a clinical-stage drug development company with our lead program DMX-200, currently in Phase II clinical trials for Chronic Kidney Disease (CKD).